A Multi-center Phase II Study with Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination with Ibrutinib in Patients with Select B-Cell Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Ublituximab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 03 Sep 2019 Status changed from active, no longer recruiting to completed.
- 10 Jul 2019 Planned End Date changed from 1 May 2019 to 1 Feb 2020.
- 26 Feb 2019 Planned End Date changed from 1 Nov 2018 to 1 May 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History